Dongcheng Pharmaceutical announced that on September 9, 2026, Yantai Dongcheng North Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Acceptance” of the marketing license application for bemipheparin sodium injection approved and issued by the State Drug Administration. The application was a registration and marketing license for domestically produced drugs, specification 0.2ml: 3,500aaiU, acceptance number CYHS2602247, and decided to accept it. This product was only originally developed and marketed domestically, with no generic drugs on the market. In 2025, the sales volume of all domestic terminal hospitals was 300 million yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.